Arcturus Therapeutics (NASDAQ:ARCT) Given Buy Rating at HC Wainwright

HC Wainwright restated their buy rating on shares of Arcturus Therapeutics (NASDAQ:ARCT) in a research note released on Monday morning,Benzinga reports. HC Wainwright currently has a $63.00 price objective on the biotechnology company’s stock.

Separately, Cantor Fitzgerald reiterated an “overweight” rating on shares of Arcturus Therapeutics in a research note on Monday, December 16th. Six analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, the company has a consensus rating of “Buy” and a consensus target price of $66.75.

Arcturus Therapeutics Stock Up 1.0 %

Shares of ARCT opened at $16.76 on Monday. Arcturus Therapeutics has a 12-month low of $14.30 and a 12-month high of $45.00. The stock has a market cap of $453.98 million, a P/E ratio of -7.55 and a beta of 2.63. The business’s fifty day moving average is $17.55 and its 200 day moving average is $19.93.

Arcturus Therapeutics (NASDAQ:ARCT) last posted its earnings results on Thursday, November 7th. The biotechnology company reported ($0.26) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.70) by $0.44. Arcturus Therapeutics had a negative net margin of 36.39% and a negative return on equity of 22.39%. The firm had revenue of $41.67 million during the quarter, compared to analyst estimates of $49.16 million. During the same quarter in the prior year, the business posted ($0.61) EPS. On average, analysts expect that Arcturus Therapeutics will post -2.31 EPS for the current year.

Hedge Funds Weigh In On Arcturus Therapeutics

Several hedge funds have recently bought and sold shares of the company. Sumitomo Mitsui Trust Group Inc. lifted its position in Arcturus Therapeutics by 45.6% during the third quarter. Sumitomo Mitsui Trust Group Inc. now owns 2,275,715 shares of the biotechnology company’s stock valued at $52,819,000 after purchasing an additional 712,650 shares during the last quarter. Millennium Management LLC increased its position in shares of Arcturus Therapeutics by 250.1% during the second quarter. Millennium Management LLC now owns 555,024 shares of the biotechnology company’s stock valued at $13,515,000 after buying an additional 396,505 shares during the period. Empire Life Investments Inc. purchased a new position in Arcturus Therapeutics during the third quarter valued at $3,498,000. ARK Investment Management LLC increased its stake in shares of Arcturus Therapeutics by 6.9% during the third quarter. ARK Investment Management LLC now owns 2,101,038 shares of the biotechnology company’s stock valued at $48,765,000 after purchasing an additional 136,074 shares in the last quarter. Finally, PDT Partners LLC purchased a new stake in shares of Arcturus Therapeutics in the third quarter worth $1,744,000. Hedge funds and other institutional investors own 94.54% of the company’s stock.

About Arcturus Therapeutics

Arcturus Therapeutics Holdings Inc, a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA.